Patents by Inventor David Telander

David Telander has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Water spillage protection for table purifier
    Patent number: 11944197
    Abstract: The disclosure relates to a table (100). The table (100) has a table top (102), a plurality of legs (104) connectable to the table top (102), and an air purifier (106) adapted to be placed below the table top (102). A bottom side of the table top (102) is provided with at least one groove (112) extending in a circumferential direction for preventing liquid from traveling from an outer edge of the table top (102) along the bottom side of the table top (102) and reaching an inner section of the air purifier (106). The disclosure also relates to a method for purifying air using a table (100).
    Type: Grant
    Filed: June 3, 2021
    Date of Patent: April 2, 2024
    Assignee: INTER IKEA SYSTEMS B.V.
    Inventors: Paul Larsson, David Wahl, Henrik Telander, Bofeng Peng, Derong Jian, Tao Wang, Zhongtao Luo, Zhisuo Chen, Dianqiu Zhang, Xiaoming Lian, Zhenqi Yan, Youxiong Zhang
  • Epithelial membrane protein-2 (EMP2) and proliferative vitroretinopathy (PVR)
    Patent number: 9464135
    Abstract: Methods of preventing retinal detachment associated with proliferative vitreoretinopathy are provided by administering agents which antagonize the activity or function of EMP2 to subjects at risk of the detachment.
    Type: Grant
    Filed: November 18, 2010
    Date of Patent: October 11, 2016
    Assignees: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE UNITED STATES OF AMERICA DEPARTMENT OF VETERAN AFFAIRS
    Inventors: Lynn K. Gordon, Shawn A. Morales, David Telander, Jonathan Braun
  • EPITHELIAL MEMBRANE PROTEIN 2 (EMP2) BINDING REAGENTS AND THEIR THERAPEUTIC USES IN OCULAR DISEASES
    Publication number: 20130034555
    Abstract: A method is disclosed for treating diseases or disorders of the eye involving undesired expression of vascular endothelial growth factor (VEGF) by administration of endothelial membrane protein 2 (EMP2) inhibitor. The present invention relates to the direct treatment of macular degeneration, particularly age-related macular degeneration (AMD), by administering an EMP2 inhibitor intraocularly or systemically.
    Type: Application
    Filed: February 22, 2011
    Publication date: February 7, 2013
    Applicants: United States Government Department of Veterans Affairs, The Regents of the University of California
    Inventors: Lynn K. Gordon, Jonathan Braun, Shawn A. Morales, David Telander, Madhuri Wadehra
  • EPITHELIAL MEMBRANE PROTEIN-2 (EMP2) AND PROLIFERATIVE VITRORETINOPATHY (PVR)
    Publication number: 20130004493
    Abstract: Methods of preventing retinal detachment associated with proliferative vitreoretinopathy are provided by administering agents which antagonize the activity or function of EMP2 to subjects at risk of the detachment.
    Type: Application
    Filed: November 18, 2010
    Publication date: January 3, 2013
    Applicants: The United States Government Department of Veteran's Affair, The Regents of the University of California
    Inventors: Lynn K. Gordon, Shawn A. Morales, David Telander, Jonathan Braun